EFB Dengue Literature Review

Wrammert2012 - Plasmablast Responses in Acute Dengue

7 min read

Wrammert2012 - Plasmablast Responses in Acute Dengue

Full citation: Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, Kwissa M, Pulendran B, Wilson PC, Wittawatmongkol O, Yoksan S, Angkasekwinai N, Pattanapanyasat K, Chokephaibulkit K, Ahmed R. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. Journal of Virology. 2012;86(6):2911–2918. doi:10.1128/JVI.06075-11

Raw file: [[raw/wrammert2012.pdf]]

Summary

This paper provides one of the earliest systematic characterisations of the acute-phase plasmablast response during human dengue virus infection. Using a cohort of 46 confirmed dengue patients (pediatric and adult) admitted to Siriraj Hospital in Bangkok, Thailand (2009–2011), the authors demonstrate a massive and rapid plasmablast expansion in peripheral blood — often exceeding 1,000-fold over healthy baseline levels and reaching up to 30% of total peripheral lymphocytes (median 3.7 × 10⁵ plasmablasts/ml blood). Plasmablasts peaked at day 6–7 post-fever onset and returned to baseline within one month of discharge.

Using ELISpot with formalin-inactivated DENV-2 (strain 16681) as capture antigen, the authors showed that the response was largely virus-specific: ≥70% of IgG-secreting plasmablasts bound DENV antigen, with minimal IgA (~100-fold lower) and near-absent IgM responses. This virus-specificity, combined with detection of cross-serotype reactivity (similar frequencies in DENV-1, -2, and -3 patients using DENV-2 antigen), argues against nonspecific bystander activation and instead reflects cognate antigen-driven, cross-reactive memory recall.

The cohort was almost exclusively secondary infections (42/46 by serology), and the response was dominated by IgG — consistent with class-switched memory B cell recall. Importantly, the clinical diagnosis of DF vs. DHF did not correlate with plasmablast magnitude or kinetics, though this was likely confounded by all patients requiring hospitalisation. The temporal coincidence of peak plasmablasts with the critical window for severe dengue pathology raises the question of whether these cells contribute to immunopathology, a hypothesis subsequently supported by GarciaBates2013 and Ansari2025.

Study Design

  • Type: Prospective observational cohort (cross-sectional sampling with some longitudinal follow-up)
  • Sample size: 46 confirmed dengue patients (28 DF, 17 DHF I/II, 1 DSS); 3 additional patients with paired acute samples; healthy controls (Thai and US)
  • Setting: Siriraj Hospital, Bangkok, Thailand; 2009–2011; single blood sample days 2–8 post-fever onset; convalescent sample at ≥1 month post-discharge in a subset
  • Population: Pediatric and adult; median age 17 (DF) and 20 (DHF); DENV-1, -2, -3 (no DENV-4); 42/46 secondary infection by IgM/IgG ratio; WHO 1997 severity classification

Key Findings

  • Massive plasmablast expansion: Plasmablasts (CD19⁺CD3⁻CD20⁻/low CD27^high CD38^high) averaged 47% of CD19⁺ B cells during acute dengue, with some patients reaching 30% of total lymphocytes. Median absolute count: 3.7 × 10⁵/ml blood (>1,000-fold over healthy baseline).
  • Peak at day 6–7 post-fever onset: Samples from days 2–3 showed near-baseline plasmablast levels; rapid increase to massive levels by day 6–7. Confirmed by paired samples in 3 donors sampled 2 days apart, each showing significant increase.
  • Magnitude dwarfs vaccination responses: Dengue plasmablast responses were significantly larger than influenza booster vaccination (peak day 7, ~2–3% of CD19⁺ B cells) or primary yellow fever vaccination (peak day 11–14) — both measured in US cohorts (p < 0.0001 for each comparison).
  • Virus-specific and IgG-dominant: ELISpot with DENV-2 antigen showed ≥70% (often ≥80%) of IgG-secreting plasmablasts were DENV-specific. IgA-secreting DENV-specific cells were present but ~100-fold lower. IgM-secreting cells were rare and never IgM-only; all four primary responders had detectable IgM responses.
  • Cross-serotype reactivity: No significant difference in DENV-specific cell frequency between DENV-2-infected patients and DENV-1 or DENV-3-infected patients (using DENV-2 capture antigen), indicating responses target shared epitopes/proteins across serotypes.
  • Serotype-independent magnitude: Absolute plasmablast numbers were similar regardless of infecting serotype (DENV-1, -2, or -3; ns for all pairwise comparisons).
  • No DF/DHF severity correlation: Clinical diagnosis (DF vs. DHF) did not correlate with plasmablast magnitude or kinetics. Authors acknowledge confounding: all patients were hospitalised (floor effect on mild disease).
  • Primary vs. secondary similar magnitude: The 4 primary responders showed responses similar to the 42 secondary responders, though too few for statistical comparison.
  • Serum IgG correlates with plasmablasts: DENV-specific serum IgG (by ELISA) correlated with both absolute plasmablast count (r² = 0.3, p = 0.02 by flow) and DENV-specific ELISpot frequency (r² = 0.4, p = 0.02).
  • Transient response: At 1-month follow-up, plasmablast numbers returned to healthy baseline levels with no detectable DENV-specific cells by ELISpot — indicating contraction through cell death or tissue migration (bone marrow homing).
  • No hypergammaglobulinemia: Despite massive plasmablast expansion, total serum IgG was not elevated above healthy controls — suggesting most plasmablasts are short-lived and do not persist as long-lived plasma cells.
  • Non-dengue febrile illness controls: Patients with hepatitis A or unidentified febrile illness also showed substantial plasmablast responses, but none were DENV-specific — confirming that the DENV-specific ELISpot discriminates true dengue responses from generic febrile activation.

Methods Used

  • Conventional Flow Cytometry (5-color: CD19-FITC, CD38-PE, CD3-PerCP, CD20-PerCP, CD27-APC; BD Trucount for absolute counts)
  • ELISpot (DENV-2 strain 16681 whole virus; IgG, IgA, IgM isotype-specific; total Ig capture)
  • ELISA (DENV-specific serum IgG; total serum IgG)

Entities Mentioned

Concepts Addressed

Relevance & Notes

This paper is foundational for the wiki’s dengue plasmablast research strand. It establishes the magnitude benchmark (~47% of B cells, >1,000-fold increase, day 6–7 peak) that GarciaBates2013 later stratified by severity (46% in severe 2° dengue) and that Ansari2025 mechanistically attributed to the Tph→IL-21→memory B cell→plasmablast axis.

Key limitations:

  • Minimal 5-color panel: CD19, CD3, CD20, CD27, CD38 only. No IgD (cannot gate DN subsets or confirm naive vs. unswitched memory), no CD21 (cannot identify atypical/EF populations), no CD11c or CXCR5 (cannot resolve DN1/DN2). This is among the simplest panels in the wiki; every subsequent dengue study (GarciaBates2013, Singh2026, Ansari2025) added markers.
  • Cross-sectional design: Single timepoint per patient (except 3 with paired samples); kinetic trajectory inferred across individuals, not within.
  • Almost entirely secondary infections: Only 4/46 primary; cannot meaningfully compare primary vs. secondary kinetics.
  • No severity discrimination: DF/DHF comparison is confounded by hospitalisation threshold. GarciaBates2013 resolved this by including outpatients and OFI controls.
  • DENV-2 as sole ELISpot antigen: Cross-serotype reactivity could not be dissected; the ≥70% specificity is a lower bound since conformational epitopes may be lost in formalin-inactivated preparation.

The paper correctly identifies the key open question that subsequent work addresses: are the antibodies produced by these plasmablasts protective, pathological (ADE), or both? The Ansari2025 neutralizing Ab paradox (FRNT₅₀ not different by severity despite massive PB expansion) and GarciaBates2013 PRNT₅₀ disconnect both answer this: the antibodies are predominantly non-neutralizing.

Questions Raised

  • What is the repertoire breadth and fine specificity of the antibodies produced by dengue plasmablasts? Are they predominantly directed at conserved cross-reactive epitopes (E protein fusion loop, prM) or at serotype-specific neutralizing epitopes?
  • What proportion of the dengue plasmablast response is functionally neutralizing vs. enhancing (ADE-competent)?
  • Do the kinetics differ between primary and secondary infection when adequately powered? (Only 4 primary cases here.)
  • Why is there no hypergammaglobulinemia despite >10⁵ ASCs/ml? This implies massive cell death — is this the same activation-induced apoptosis mechanism described by GarciaBates2013 (caspase-3⁺)?
  • What is the Fc glycosylation pattern of plasmablast-derived IgG in dengue? The authors raise this as a potential mechanism for pro-inflammatory antibody function — an unexplored angle.

Graph View

Backlinks